Form 8-K - Current report:
SEC Accession No. 0001628280-24-000676
Filing Date
2024-01-05
Accepted
2024-01-05 17:03:01
Documents
12
Period of Report
2024-01-04
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K prme-20240104.htm   iXBRL 8-K 24051
  Complete submission text file 0001628280-24-000676.txt   152759

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prme-20240104.xsd EX-101.SCH 1919
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prme-20240104_lab.xml EX-101.LAB 24834
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prme-20240104_pre.xml EX-101.PRE 13055
6 EXTRACTED XBRL INSTANCE DOCUMENT prme-20240104_htm.xml XML 2912
Mailing Address 21 ERIE ST. CAMBRIDGE MA 02139
Business Address 21 ERIE ST. CAMBRIDGE MA 02139 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41536 | Film No.: 24517393
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)